𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease

✍ Scribed by T. Leyhe; Elke Stransky; G. W. Eschweiler; G. Buchkremer; C. Laske

Publisher
Springer-Verlag
Year
2007
Tongue
English
Weight
200 KB
Volume
258
Category
Article
ISSN
1433-8491

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tolerability of switching from donepezil
Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease
✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving

Remarkable increase in the concentration
Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease
✍ Takashi Abe; Hideo Tohgi; Chiaki Isobe; Takahiko Murata; Chigumi Sato 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract To investigate the possible role of oxidative RNA damage in the pathogenesis of Alzheimer's disease (AD), the concentrations of the oxidative stress marker 8‐hydroxyguanosine (8‐OHG) were measured in the cerebrospinal fluid (CSF) and the serum of patients with AD and control subjects. T

Donepezil for the symptomatic treatment
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
✍ Anne Whitehead; Carlos Perdomo; Raymond D. Pratt; Jacqueline Birks; Gordon K. Wi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

## Abstract ## Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). ## Method A systematic review of individual patient data from Phase II and III do